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Abstract
Background: CRISPR genome-editing technology makes it possible to quickly and cheaply delete non-protein-coding
regulatory elements. We present a vector system adapted for this purpose called DECKO (Double Excision CRISPR
Knockout), which applies a simple two-step cloning to generate lentiviral vectors expressing two guide RNAs (gRNAs)
simultaneously. The key feature of DECKO is its use of a single 165 bp starting oligonucleotide carrying the variable
sequences of both gRNAs, making it fully scalable from single-locus studies to complex library cloning.
Results: We apply DECKO to deleting the promoters of one protein-coding gene and two oncogenic lncRNAs, UCA1
and the highly-expressed MALAT1, focus of many previous studies employing RNA interference approaches. DECKO
successfully deleted genomic fragments ranging in size from 100 to 3000 bp in four human cell lines. Using a
clone-derivation workflow lasting approximately 20 days, we obtained 9 homozygous and 17 heterozygous
promoter knockouts in three human cell lines. Frequent target region inversions were observed. These clones
have reductions in steady-state MALAT1 RNA levels of up to 98 % and display reduced proliferation rates.
Conclusions: We present a dual CRISPR tool, DECKO, which is cloned using a single starting oligonucleotide,
thereby affording simplicity and scalability to CRISPR knockout studies of non-coding genomic elements,
including long non-coding RNAs.
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Background
The recent invention of genome-editing techniques marks
a change in genomics from an observational to an experi-
mental science. By deleting, editing, activating or repres-
sing genomic elements at will, we can test their function
in a natural setting [1]. This makes it possible for the first
time to comprehensively study the function of thousands
of non-protein-coding genomic regulatory elements and
RNAs that have been recently discovered in the human
genome [2]. In this study we adapt the CRISPR approach
to the targeted deletion of non-coding elements, and dem-
onstrate its utility in the silencing of long non-coding
RNA (lncRNA) genes by promoter deletion. The key
advance presented here is the use of a single starting
oligonucleotide for cloning a dual gRNA expression vec-
tor, conferring both convenience and scalability.
CRISPR (Clustered Regularly Interspaced Short
Palindromic Repeats) is a natural bacterial immunity
system, with huge potential as a simple, cheap and
versatile genome editing system [3]. Repurposed as
an experimental tool, the system has two compo-
nents: first, a bipartite small RNA, or “guide RNA”
(gRNA), designed to recognise a specific location in
the genome; second, the Cas9 protein that binds the
gRNA and is thereby recruited to the target site.
The gRNA consists of a 20 nt targeting region that
hybridises to genomic DNA upstream of a dinucleo-
tide protospacer adjacent motif (PAM, here NGG),
fused with a scaffold sequence recognised by Cas9
protein [3]. By engineering the gRNA targeting re-
gion, one may target virtually any complementary
genomic locus with moderate off-target effects [4].
As an effector protein, Cas9 may either be employed
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as a natural nuclease [1, 5], or else catalytically inac-
tivated and fused to a different protein domain [6].
These features make it possible to manipulate the
numerous types of non-protein coding genomic ele-
ments that have so far resisted standard RNA inter-
ference (RNAi) techniques [6, 7].
The study of one gene class in particular, long non-
coding RNAs (lncRNAs), has been hindered by a lack of
effective loss-of-function tools [2]. Numerous yet poorly
characterised, >40,000 lncRNAs have been discovered in
the human genome, yet we understand the molecular
function of <1 % [8]. This gap in understanding is exac-
erbated by the difficulty of studying lncRNA by conven-
tional approaches. The traditional path of reverse
genetic gene targeting for the entire lncRNA catalogue is
not feasible [9–12]. Furthermore, doubts have been
raised as to whether the observed phenotypes in knock-
out animals are the result of the loss of the lncRNA it-
self, or of an overlapping gene regulatory elements [13].
Post transcriptional RNAi approaches regularly fail for
lncRNA for reasons as yet unknown, and may only be
capable of acting on cytoplasmic RNA populations [14].
Moreover, RNAi is transient and often incapable of re-
ducing targeted RNA levels beyond 50 % [15]. Finally,
other elements such as enhancers or microRNA genes
are not substrates for the RNAi pathway.
Another approach worthy of mention is gene silencing
through integration of destabilising sequences by zinc
finger nucleases. Using this method, Diederichs and col-
leagues managed to stably reduce levels of the MALAT1
lncRNA around 1000-fold in cell clones [16]. While ef-
fective, such approaches require a homology construct
and zinc finger nuclease that is specific to each target
gene, introducing an element of complexity and ruling
out large-scale screening approaches.
Against this backdrop CRISPR-based deletion holds
great promise as a tool for loss-of-function studies in
non-coding RNAs and genomic elements [5, 17–20].
Two distinct gRNAs flanking the target region are intro-
duced in combination with a catalytically active Cas9.
The cellular non-homologous end-joining (NHEJ) mech-
anism repairs the resulting break [12], and in a certain
proportion of cells, one or all alleles are correctly de-
leted. This approach is capable of removing regions from
approximately 102 to 106 base pairs, and there is an in-
verse relationship between efficiency of deletion and tar-
get region size [19]. This versatility means that CRISPR
deletion has been used successfully for knocking out
protein-coding genes [17], enhancers [21] and micro-
RNAs [22].
One of the most exciting applications of CRISPR is the
cell-based pooled screening of many thousands of gen-
omic elements in parallel [6, 23, 24]. This is carried out
using vector pools expressing ~10,000 unique gRNA
sequences, cloned using the synthesised oligonucleotide
libraries of up to 200 bp [25]. Such screens require the
introduction of one single viral sequence, and hence one
CRISPR construct, per cell. While this is feasible for
studies of protein-coding genes, where a frameshift indel
caused by a single gRNA is sufficient to disrupt an entire
gene [6, 23, 24], this is not the case for non-protein cod-
ing elements, which require paired gRNAs as discussed
above. This introduces the need for vector systems that
are capable of [1] expressing dual gRNAs from a single
plasmid, and [2] are compatible with oligonucleotide li-
brary cloning. While the first condition alone has been
met by a number of recent approaches [26–28], the
present study describes a method that fulfills both by
cloning a dual gRNA expressing plasmid using a single
starting oligonucleotide.
In this study we present a CRISPR-based knockout
strategy with general applicability to almost any genomic
element of <1 Mb. This system, DECKO (Double Exci-
sion CRISPR Knockout), is novel for the fact it expresses
dual gRNAs from a single plasmid, which is cloned using
a single starting oligonucleotide. This, coupled with the
lack of homology plasmid, makes the method in principle
scalable from single-gene studies to high-throughput
screens, while also simplifying the derivation of stable
knockout cell clones. We here demonstrate the utility of
this approach in studying lncRNAs by deleting the
promoter of the MALAT1 lncRNA and other genes in a
number of human cell lines.
Results and discussion
Dual excision CRISPR knockout design
CRISPR can be used to delete genomic sequences, by
cutting genomic DNA at two sites and relying on non-
homologous end-joining (NHEJ) mechanism to repair
the break (Fig. 1a). gRNAs are introduced to cells by a
plasmid vector, either through transfection or viral infec-
tion. As it does not vary between experiments, the scaf-
fold (constant region) sequence is encoded within the
expression plasmid [23]. In contrast, the variable 20 nt
target region must be generated in each experiment by
the cloning of synthesised DNA fragment into the tar-
geting vector. In the past, genomic deletion experiments,
which require two separate gRNAs, has been achieved
by co-transfecting independent plasmids, each express-
ing a single gRNA [5, 17, 20, 22], or else sequentially
cloning two gRNA sequences into a single backbone
[22]. While effective, this approach suffers from draw-
backs due to the requirement for cloning two independ-
ent targeting constructs.
To facilitate the disruption of individual lncRNAs and
for eventual pooled functional screens of many lncRNAs,
we devised a protocol for the simultaneous cloning of two
distinct guide RNA sequences into a single lentiviral
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vector, which we call DECKO (Dual Excision CRISPR
Knock Out) (Fig. 1b). Both gRNAs’ targeting sequence is
synthesised as a single 165 bp DNA fragment. The
DECKO vector (hereafter, pDECKO) preparation protocol
comprises two cloning stages. First, the synthesised DNA
fragment “Insert-1”, containing the targeting regions of
the two gRNA sequences separated by a cloning site
(Fig. 1e), is inserted into BsmBI sites of parental plasmid
by means of Gibson assembly cloning (Fig. 1c). As a Type
IIS restriction enzyme, BsmBI cuts downstream of its
recognition site, allowing scarless cloning of the gRNA
sequence.
In the second cloning step, the resulting intermediate
plasmid is opened at two positions by a second BsmBI
digestion at the cloning sites within Insert-1, and a
second DNA fragment “Insert-2” is inserted by conven-
tional ligation, in the process removing both BsmBI sites
(Fig. 1d). Insert-2 carries the gRNA constant region
coupled to an H1 promoter, and does not vary between
experiments. The final plasmid, suitable for transfection
or lentivirus production, is capable of the independent
transcription of two gRNA molecules (Fig. 1b). To avoid
possible recombination or regulatory interference, gRNA
genes are driven by two distinct, high-strength RNA
Polymerase III promoters: human H1 and human U6
[29–32]. The entire cloning protocol lasts around 5 days,
not including DNA fragment synthesis and clone valid-
ation by Sanger sequencing.
Design of pDECKO constructs targeting lncRNA gene
promoters
To test DECKO, we attempted to knock out two onco-
genic long noncoding RNA genes that have been the
subject of numerous previous RNAi studies: MALAT1
[16] and UCA1 [33], in addition to the protein-coding
TFRC gene encoding an easily-detected surface marker
protein [6].
As a general strategy for gene silencing, we chose to
delete gene promoters [5]. This approach has several ad-
vantages over the conventional alternative of removing
the entire gene sequence. First, it means that the region
to be deleted can be in the size range 0.5–3 kb, enabling
higher knockout efficiency than knockouts of 10–100 kb
required for most genes [19]. Second, it means that the
deleted region does not vary as a function of gene
length, reducing variability between experiments. Finally,
by deleting smaller regions, we can be more confident
that observed phenotypic effects are due to loss of
lncRNA transcription, and not an unintended conse-
quence of deleting overlapping genomic regulatory ele-
ments [13].
We designed a series of targeting constructs (Table 1,
Fig. 2 and Additional file 1: Figure S1) intended to re-
move varying-sized fragments encompassing the pro-
moter and transcription start site (TSS) of the target
gene set (MALAT1, TFRC and UCA1). Our selection of
promoter regions was guided by both Gencode gene an-
notations [34] and RNA sequencing data from human
cell lines from ENCODE [35]. These fragments vary in
size from 100 to 3000 bp. In the case of MALAT1, we
targeted both the major promoter, which seems to drive
the majority of transcription, as well as a second an-
notated upstream promoter. Molecular cloning was
carried out as described above, resulting in a full set
of sequence-verified pDECKO vectors.
Expression of gRNAs from a single plasmid
We began by testing whether the pDECKO configur-
ation is capable of expressing high levels of both gRNAs
simultaneously. pDECKO plasmids were transfected into
HCT116 colorectal carcinoma cells and HeLa cells, se-
lected with puromycin and RNA was extracted. Using
quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR) and specific primers (Fig. 3a), we ob-
served expression for all gRNA pairs in the two human
cell lines (Fig. 3b,c). Expression in HeLa (Fig. 3c) ap-
peared more balanced between U6- and H1-driven tran-
scripts than in HCT116 (Fig. 3b), where H1 appears to
be generally the stronger promoter.
Knockout of genomic fragments by DECKO
To examine the efficacy of pDECKO in gene silencing,
we began by examining performance in bulk cells. In
these experiments, although antibiotics are used to select
for transfected cells, we did not attempt to isolate those
cell clones where CRISPR deletion has successfully taken
place. Given that (a) this cutting is a stochastic event
with a defined efficiency, and (b) target site deletion de-
pends on simultaneous cutting at two locations in one
or more alleles by CRISPR, it is reasonable to expect
that such bulk populations should contain a mixture of
wild type, heterozygous and homozygous knockout cells.
(See figure on previous page.)
Fig. 1 Outline of DECKO. a Deletion of genomic elements such as promoters by dual CRISPR targeting. b Structure of pDECKO. Two independent gRNA
transgenes are driven by human U6 and human H1 promoter sequences. Variable sequence are highlighted in blue. c Cloning step 1: Synthesised
oligonucleotide Insert-1, carrying all variable sequence, is inserted into BsmBI-digested parental plasmid by Gibson assembly. d Cloning step 2:
the preassembled universal Insert-2 is inserted into the intermediate plasmid by standard ligation. e Nucleotide sequence of the 165 nt Insert-1.
From left to right: Light orange: 5’ Gibson assembly overhang; light blue: targeting region of gRNA1; grey: fragment of first scaffold region; yellow:
BsmBI sites; dark blue: target region of gRNA2; dark orange: fragment of H1 promoter; grey: 3’ Gibson assembly overhang
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We transfected pDECKO plasmids into a variety of
human cell lines in the presence of either cotransfected
or stably-expressed catalytically-active Cas9 nuclease.
Excision was tested qualitatively by genomic PCR using
primers flanking the genomic target region, such that
correctly deleted alleles should produce a shorter PCR
product than the wild-type uncut allele (Fig. 4a). Using
HeLa cells transfected with the TFRC_B pDECKO plas-
mid (Fig. 4b), we observed a mixture of short and long
PCR products of lengths expected for knockout and wild
Table 1 Targeting constructs used in this study
Targeted gene Length of cut Position to TSS Target region Expected PCR size (WT)(bp) Expected PCR size (KO)(bp)
MALAT1_A 100 bp −70/+30 Upstream TSS 278 166
MALAT1_B 500 bp −400/+100 Upstream TSS 641 123
MALAT1_C 600 bp −430/+240 Major TSS 871 148
MALAT1_D 600 bp −450/+260 Major TSS 871 109
MALAT1_E 3000 bp −500/+2500 Both TSS 3249 224
UCA1 500 bp −480/+160 819 181
TFRC_A 100 bp −70/+30 215 97
TFRC_B 500 bp −400/+100 637 141
TFRC_C 1000 bp −700/+300 1240 239
Fig. 2 Targeting promoter regions of genes for knockout. a The structure of the MALAT1 locus showing the major promoter and upstream
promoter. The MALAT1 transcript annotations from Gencode version 19 (green) lie on the positive strand. Coloured bars indicate regions targeted
by CRISPR deletion in this study. Shown below are ENCODE whole cell polyA+ RNA sequencing read density for three of the cell lines used,
showing that the majority of transcription originates at the major promoter. The four primer sets for qRTPCR are shown. b The TFRC gene locus.
Coloured bars indicate regions targeted by CRISPR deletion. In black, the amplicon used for qRTPCR
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type, respectively. These bands were confirmed to ori-
ginate from the TFRC promoter by Sanger sequencing.
We went on to test the TFRC_B construct in IMR90
foreskin fibroblasts, HCT116 (Fig. 4c) and HEK293T hu-
man epithelial kidney cells (Additional file 2: Figure
S2A), observing in all cases short PCR products resulting
from successful promoter deletion.
We next tested the effectiveness of lncRNA promoter
pDECKO constructs. For vectors targeting the upstream
(MALAT1_A) and major (MALAT1_C) promoters, we
observed successful deletion in four different cell lines:
HeLa, HEK293T, IMR90 and HCT116 (Fig. 4d and e,
and Additional file 2: Figure S2B-E). We also success-
fully deleted the UCA1 promoter region in HEK293T
cells (Additional file 2: Figure S2F). In all cases we ob-
served a mixture of deleted and wild type alleles. Given
differences in PCR amplification efficiencies and product
length, it is not possible to directly infer the relative pop-
ulations of these alleles given the band intensity alone. It
is important to note that IMR90 are karyotypically nor-
mal and HCT116 are near diploid, while HeLa and
HEK293T are aneuploid [36, 37]. HeLa cells are pseudo
triploid, meaning that they are likely to carry three cop-
ies of the MALAT1 locus [36]. Altogether out of 9
DECKO plasmids tested, 8 were successful in deleting
their target region in bulk cells (TFRC_A construct
yielding no detectable cutting).
Promoter knockout in bulk cells should result in loss
of steady-state RNA levels of the targeted genes. We
tested TFRC and MALAT1 genes by qRT-PCR across all
tested cell lines (Fig. 4f-h and Additional file 3: Figure
S3). The steady-state levels of TFRC mRNA was reduced
by around 50 % in both IMR90 and HCT116 cells
(Fig. 4f ). We also confirmed that this results in a loss of
TFRC protein expression. Using flow cytometry analysis
on cells stained with α-TFRC-FITC antibody, we ob-
served a corresponding reduction in fluorescence of
HCT116 cells transfected with TFRC_B plasmid (Fig. 4i).
Similarly we investigated the effect on MALAT1 RNA
from CRISPR treatment in bulk cells. Deletion of the up-
stream promoter by the MALAT1_A sequences had no
detectable effect on RNA levels in bulk cells (Fig. 4g). In
Fig. 3 Expression of gRNAs. a Primer design for specific detection of gRNAs by qRTPCR. The reverse primer is constant for all PCRs while a
specific primer is designed for each gRNA. (b and c) Relative expression of transfected gRNAs in HCT116 cells (b) and Hela cells (c). Cells were
transfected and selected with puromycin (2ug/mL) for 3 days. Data are normalised to the housekeeping gene GAPDH. Control amplifications
were carried out using indicated primers with cDNA template from pDECKO-GFP cells
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Fig. 4 Sequence deletion in bulk cells. a Outline of the genomic PCR (gPCR) primer strategy used for genotyping. b Deletion of TFRC promoter
(construct B in Fig. 2), as validated by electrophoresis of gPCR products. Wild type gDNA and water templates are used as positive and negative
controls, respectively. Green and red arrows indicate the size of PCR products expected from wild type (WT) and deleted alleles. Note that in this
and subsequent panels, separated lanes originate from the same original agarose gel, rearranged for clarity. c-e gPCR on bulk cells transfected
with the indicated DECKO plasmids targeting (c) TFRC promoter, (d) MALAT1 upstream promoter, (e) MALAT1 major promoter. (f-h) qRTPCR on
cell samples shown in (c-e). Control indicates RNA from cells transfected with a DECKO targeting GFP. Levels were normalised to GAPDH. Error
bars show the standard deviation of three technical replicates. i Expression of TFRC protein on cell surface, as determined by flow cytometry
analysis of antibody-stained cells. Left: histogram of cell fluorescence intensity counts. Right: Calculation of relative stain index, a normalised measure of
fluorescence intensity
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contrast, removal of the major promoter (MALAT1_C)
resulted in a clear reduction of RNA levels in both HeLa
and HEK293T cells (Fig. 4h).
We observed similar results for other cell lines/
pDECKO combinations, although in some cases such
as TFRC_B in HEK293T we could observe no
detectable reduction in target gene expression
(Additional file 3: Figure S3). Thus, DECKO is cap-
able of deleting target regions and may be optimised
to achieve moderate levels of RNA knockdown in
bulk cells that may be useful in some experimental
contexts.
Generation of knockout cell clones
We next sought to isolate individual cell clones carrying
heterozygous or homozygous promoter deletions. Clone
derivation tends to be time-consuming, given the neces-
sity of deriving individual cell clones and genotyping
them. We sought to streamline this as much as possible,
through the use of FACS single cell sorting and direct
PCR from cell lysates (Fig. 5a).
Cells were transfected as before with pDECKO con-
structs. This time, cells were separated into single clones
by FACS and expanded in culture. We concentrated on
HCT116, HeLa and HEK293T, since these cells could
Fig. 5 Derivation of TFRC cell clones. a Outline of the clone-derivation protocol used for TFRC and MALAT1 knock out cells, indicating approximate
time required. b First and c second stage PCRs to genotype clones. Primer combination schemes are indicated below the electrophoresis gels. H:
TFRC_B cell clone genotyped as heterozygote; WT, cell clones genotyped as wild type; +, positive control wild type cells; H2O, water. d qRTPCR for
TFRC mRNA, normalised to GAPDH. Error bars indicate the standard deviation of three technical replicates. e Flow cytometry analysis of surface levels
of TFRC protein. Left: histogram of cell fluorescence intensity counts. Right: Calculation of relative stain index. f Sequencing analysis of mutant junction
of the heterozygous clones. In red, region complementary to the gRNA variable region; Green, PAM sequences; Blue, indel. Expected cut location is
marked with vertical bar
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proliferate from individual clones. As before, cells were
genotyped by genomic PCR, producing one of three pos-
sible outcomes: wild type cells, displaying a long PCR
product only; heterozygous knock outs, producing both
short and long PCR products of excised and wild type
alleles; and homozygous knock outs with unique short
PCR bands. We were concerned that in these experi-
ments, the shorter knockout template might amplify
more efficiently than the long, resulting in a single short
band for heterozygous clones. To avoid this resulting in
misidentifying heterozygous clones as homozygous, we
performed an additional 2nd PCR using a primer internal
to the deleted region, which will only amplify wild type
alleles (Fig. 5b and c). A band in the 2nd PCR, coupled
with a short knockout band in the 1st PCR, thus indi-
cates a heterozygous clone, as shown for the TFRC_B
heterozygous clone (H) shown in Fig. 5b and c. Target
fragment inversion is also a commonly observed event
in experiments of this type [38, 39]. Such events will be
expected to produce a wild-type-like long PCR product,
possibly being misinterpreted as a wild-type allele.
Therefore to identify such events, it is also necessary to
genotype using an inverted internal primer (Additional
file 4: Figure S4). We show below that, for the purpose
of gene silencing, promoter inversion events are equiva-
lent to deletion.
Using this combined genotyping approach, we tested
the frequency of heterozygous and homozygous knock-
outs across 5 to 36 clones for each construct that was
genotyped (Table 2), observing variable success rates.
We observed higher rates of heterozygous compared to
homozygous clones, (17 and 9, Table 2), out of a total of
220 tested.
For TFRC, we first derived two heterozygous knockout
clones for TFRC_B, one in HEK293T and one in
HCT116, that were studied more in detail. In HCT116,
qRT-PCR analysis showed that the TFRC mRNA was
downregulated by 48 %, consistent with the loss of one
allele (Fig. 5d). To examine the effect on protein expres-
sion, we performed flow cytometry using cells stained
with α-TFRC-FITC (Fig. 5e). Consistent with mRNA
results, there was an approximately 50 % decrease in
TFRC immunofluorescence by this method compared to
control cells, exceeding the decrease previously observed
in bulk cells (Fig. 4i).
Sanger sequencing was performed on the region span-
ning the deleted TFRC promoter. The HEK293T hetero-
zygous clone had the expected junction sequence of
Cas9 cleavage between nucleotides 17 and 18 in the
gRNA2, and one extra nucleotide on gRNA1 cut;
whereas HCT116 heterozygous clone had the cutting
sites 9/15 bp from the expected ones, with short frag-
ments of inserted sequence (Fig. 5f ).
In efforts to isolate TFRC homozygous knockout cells,
we performed an additional clone derivation experiment
using HEK293T and HCT116 cells with TFRC_B and
TFRC_C DECKO constructs. Out of those 59 clones
which gave rise to viable cultures, genotyping yielded a
total of 8 heterozygous clones and zero homozygous
clones. These results, in addition to the overall low
number of viable cultures (59 out of 1152 clones sorted),
leads us to tentatively propose that TFRC−/− clones have
reduced viability.
Homozygous knockout of MALAT1 promoter as an
effective tool for gene silencing
We next derived a series of MALAT1 knockout clones
with the same strategy described for TFRC (Fig. 5a),
obtaining a total of 10 heterozygous and 9 homozygous
clones in HCT116, HeLa and HEK293T (Table 2 and
Fig. 6a-d). These clones were genotyped by three-step
PCR as described for TFRC above. We sought to
Table 2 Frequency of clone derivation
Cell type Target Clones tested WT clones Heterozygous clones Homozygous clones ND
HCT116 MALAT1_A 15 10 1 4 0
HCT116 MALAT1_B 17 17 0 0 0
HCT116 TFRC_B 36 28 3 0 5
Hela MALAT1_C 26 23 2 1 0
Hela MALAT1_D 22 21 0 0 1
Hela MALAT1_E 23 18 1 2 2
Hela TFRC_B 12 12 0 0 0
HEK293T MALAT1_C 12 10 1 1 0
HEK293T MALAT1_D 6 3 2 1 0
HEK293T MALAT1_E 5 5 0 0 0
HEK293T TFRC_B 22 10 6 0 6
HEK293T TFRC_C 24 2 1 0 21
ND – not determined
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confirm that deletion of MALAT1 major promoter re-
sulted in expected loss of steady state RNA levels in
knockout clones (Fig. 6b-d), as we previously observed
in bulk cells. Using primers in the body of the gene,
downstream of both promoters, we performed qRT-PCR
across the range of cell clones with heterozygous (Het)
and homozygous (KO) deletion of MALAT1 promoter.
Similar to results in bulk cells, clones lacking the up-
stream promoter region of MALAT1 do not display a
strong reduction in RNA levels (Fig. 6a). None of the
KO clones achieved 50 % reduction in RNA levels and
one clone displayed a moderate increase (MALAT1_A
KO1). This latter may reflect natural epigenetic variabil-
ity amongst cell clones, since two other similar knockout
clones (MALAT1_A KO2,3) show a weak reduction in
RNA levels (Fig. 6a). Similar variability amongst knock-
out clones has been observed previously [16].
Clones lacking the major promoter of MALAT1 dis-
play stronger effects on expression. The single heterozy-
gous promoter deletion of the C construct that we
obtained in HCT116 cells resulted in RNA levels 57 %
of wild type (Fig. 6b). In HEK293T, heterozygous and
KO cells yielded reductions of MALAT1 RNA to be-
tween 25 and 2 % of control cells (Fig. 6c), and of be-
tween 41 and 12 % in HeLa (Fig. 6d). These rates are
comparable to or exceed the performance of siRNAs, al-
though not competitive with destabilisation approaches
utilising homologous recombination [16]. Clones with
heterozygous promoter knockouts did have reductions
comparable to some full knock outs (Fig. 6c). Similar re-
sults were observed using semi-quantitative RTPCR
(Fig. 6e). These reductions in expression were also ob-
served using three additional primer sets at downstream
locations in the MALAT1 gene (Fig. 6f, g and Additional
file 5: Figure S5).
We used Sanger sequencing to examine at single-base
resolution the mutated sites in these cells, where neces-
sary using TA cloning to isolate individual alleles. For
MALAT1_A KO clones, three had the expected cut in
both alleles, while one clone had the expected cut in one
allele and a single indel in the other (Fig. 6h). For
MALAT1_C and D, all clones had the expected cutting
site at both alleles except for HEK293T MALAT1_D KO
clone, which contained 100 bp of extra sequence be-
tween target sites (data not shown).
MALAT1 is a potent proto-oncogene, and reduction
in MALAT1 RNA leads slowing of proliferation in a
wide range of transformed cells [40]. We used cell
growth as a phenotype by which to gauge the effective-
ness of DECKO in reducing MALAT1 activity. Homozy-
gous and heterozygous pMALAT HEK293T clones were
tested over 72 h in standard proliferation assays (Fig. 6i).
These cells displayed a clearly lower growth rate com-
pared to control cells treated, starting at 24 h post-
seeding. MALAT1_C KO cells, with the greatest loss of
MALAT1 expression (Fig. 6c), show the most severe re-
duction in proliferation, with approximately half the cel-
lular population at 72 h compared to the control clone
(pDECKO-GFP).
Conclusions
We have presented DECKO, a new strategy for the der-
ivation of knockout clones for essentially any non-
coding genomic element, including long non-coding
RNAs. The key feature of the system are [1] its delivery
of two distinct gRNAs from the same viral vector, [2]
the synthesis of all variable sequence in a single DNA
fragment at the initial cloning phase, [3] its lack of re-
quirement of a homology construct. Together these fea-
tures make DECKO not only practical for knockout of
individual sites, but for screening approaches that re-
quire multiplex cloning of many target constructs in a
pooled format [23, 41, 42]. The array-based megasynth-
esis required to produce such oligonucleotide libraries
are capable of generating pools at the 165 bp length re-
quired by DECKO [23, 25, 43].
DECKO was specifically designed with the knockout
of long non-coding RNAs in mind. LncRNA are likely to
include many thousands of genes with roles in funda-
mental biological and disease processes [17]. Unfortu-
nately progress in testing these genes’ functions at the
experimental level has been hampered by the technical
(See figure on previous page.)
Fig. 6 Derivation of MALAT1 knockout clones. a MALAT1 RNA expression levels of three HCT116 clones lacking the upstream promoter, deleted
using the MALAT1_A DECKO construct. KO, homozygous knockout. Expression detected using Primer Set 1 (see below) and values are relative
to a control cell clone expressing pDECKO GFP gRNAs. Error bars indicate the standard deviation of three technical replicates. b As for (a) in a
heterozygous clone for the major promoter, deleted using the DECKO_C construct. Het, heterozygote. c MALAT1 expression in HEK293T cells
heterozygous or homozygous for the major promoter, deleted using the DECKO_C & D constructs. Expression detected using Primer Set 1. d
As for (c) in HeLa clones, using the DECKO_C & E constructs. e Semi-quantitative PCR carried out on the same HEK293T clones that in Fig. 6c.
“RT-“indicates control samples where Reverse Transcriptase was omitted. f-g qRTPCR using three additional downstream primer pairs (see Fig. 2a),
illustrating knockdown of MALAT1 RNA throughout the gene, for the HEK293T and HeLa MALAT1_C clones. h Sequence analysis of mutant
junctions. MALAT1_A KO 3 contains one extra C in the deletion point. MALAT1_A 1, MALAT1_A 2 and MALAT1_A 4 have the expected deletion,
with no indel. Both gRNA are in antisense direction. Expected cut location is marked with vertical bar. i Proliferation assay comparing the growth
rates of control GFP and MALAT1 HEK293T knockout and heterozygous clones. Error bars indicate standard deviation of five cell wells. **, P < 0.01/***,
P < 0.001 by Student’s one-sided, paired t test
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difficulty in manipulating them. We show that CRISPR
in general, and DECKO specifically, can be used effect-
ively to knock down lncRNA expression, paving the way
for comprehensive functional testing. What is more, the
versatility of CRISPR means that it should be possible to
delete individual exons, or even fragments of exons of
lncRNAs, allowing us to experimentally dissect the func-
tionality of these genes at a level that has been impos-
sible until now.
DECKO was effective in deriving knockout cell lines:
8/9 pDECKO constructs cut their intended target region
in bulk studies. We designed a clone-selection workflow
based on cell-sorting and direct genomic PCR to derive
and genotype knockout clones with relatively low hands-
on time. Altogether we managed to derive 9 homozy-
gous knockout clones, representing 4 distinct CRISPR
targeting constructs in 3 different cell lines. These
homozygous clones were derived at a rate of between 1/
26 and 4/15 clones tested for MALAT1. Heterozygous
knockout clones were derived at a slightly higher rate:
17 individual clones from nine construct/cell combina-
tions, with a maximum frequency of 2/6 clones tested.
These knockout clones had the desired phenotypic ef-
fects: RNA levels were reduced to between 2 and 41 %
of control levels, resulting in a reduction of cellular pro-
liferation, a key MALAT1 phenotype. Together these
findings show that DECKO is a practical way of knock-
ing out lncRNAs, within reach of a typical molecular
biology laboratory, and there remains scope for further
efficiency improvements in future.
CRISPR genome editing enables us to directly observe
the effect of genomic perturbations of gene regulatory
elements. In the case of MALAT1, we have shown that
CRISPR can be used to dissect gene regulatory se-
quences by demonstrating that the annotated upstream
promoter of MALAT1 is largely irrelevant for correct
gene expression in the cells used here.
While DECKO was designed with future pooled
screening experiments in mind, a number of technical
considerations remain. First, pooled screening requires
the delivery of a single viral particle per cell. In fu-
ture experiments it will be necessary to demonstrate
that DECKO functions efficiently when expressed
from a single genomic integration, as opposed to
multiple copies of transfected plasmid. This is related
to the general challenge of improving CRISPR effi-
ciency, which is presently hampered by the large size
of the Cas9 protein and our limited understanding of
optimal gRNA targeting [44]. A second consideration
relates to annotation of target regions: lncRNA pro-
moters are often poorly annotated [2], and a suitable
DECKO library design strategy will have to flexible




gRNA sequences were designed with the CRISPR Design
tool from MIT (http://crispr.mit.edu/). U6-driven gRNAs
were required to start with a G, while H1-driven gRNAs
could start with any nucleoside. The highest scoring
gRNAs within a window of 200 bp were chosen
(Additional file 6: Table S1).
Design and cloning of plasmids
Insert-1 sequences were designed by combining the two
designed target sequences with simple design template
(available as Additional file 7: File S1). These were
synthesised as DNA oligonucleotides (gBlock, IDT) of
165 bp at a concentration of 20 ng/ul, and cloned using
Gibson assembly method [45] into lenti-guide puro plas-
mid (Addgene ref. 52963) [24] digested with BsmBI
(Thermo Fisher). We mixed 20 ng of Insert-1 with 100–
150 ng of BsmBI-digested plasmid in 10 ul volume, with
10 ul of 2x Gibson mix (note that this step could also be
carried out using commercially-available Gibson assem-
bly reagents). We incubated the mixture at 50 °C for
1 h, and fast transformed 2 ul of this into 50 ul of z-
Stbl3 competent cells (prepared with Mix and Go E.coli
Transformation Kit, Zymo Research). The resulting
intermediate plasmid, that contained additional internal
BsmBI sites, was digested with BsmBI and dephosphory-
lated with alkaline phosphatase (Thermo Fisher EF0654).
The Insert-2 sequence was previously assembled from
four oligonucleotides (IDT) (Additional file 6: Table S2).
These were annealed by mixing each oligo at a final con-
centration of 10 uM in 10 ul final volume, denatured for
5’ at 95 °C and cooled to 25 °C at a ramp rate of 0.1 °C
per second. Then, a ligation reaction was performed
with 50 ng of BsmBI-digested intermediate plasmid, 1 ul
of annealed Insert-2 (diluted 1:20) and 1 ul of Quick
ligase (Biolabs) and incubated 10 min at room temperature.
5 ul of the ligation product was transformed into 50ul of z-
Stbl3 competent cells. Clones were tested by colony PCR
and by Sanger sequencing using primer sequences found in
Additional file 6: Table S3.
Cell lines and culture
All cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Life Technologies), except for IMR90
that were grown in Eagle’s Minimum Essential Medium
(EMEM, ATCC). Media were supplemented with 10 %
fetal bovine serum (FBS, Gibco), 5 % Penicillin-
Streptomycin Streptomycin (Life Technologies). Cells
were maintained at 37 °C in a humid atmosphere con-
taining 5 % CO2 and 95 % air. Cells were transfected
with Lipofectamine 2000 (Life Technologies) following
the manufacturer’s protocol. For lentivirus production,
pDECKO plasmid was co-transfected into HEK293T
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cells with the packaging plasmids pVsVg (AddGene 8484)
and psPAX2 (Addgene 12260).
For creating the Cas9 stable expressing cell lines, we
transfected Cas9 plasmid with blasticidin resistance
(Addgene 52962) and selected for more than 5 days with
blasticidin (4ug/ml for HeLa cells and 10ug/ml for
IMR90 cells).
When cotransfecting the Cas9 plasmid (Addgene 52962)
together with the gRNA plasmid (pDECKO, that contains
puromycin resistance), we selected for at least 2 days with
puromycin (2ug/ml).
Clone derivation and genotyping
Cells were sorted for single cell in FACS Aria or FACS
Influx and plated in 96 well plates, then cultured for ap-
proximately 10 days until sufficiently numerous for
genotyping. Surviving clones were transferred to 24 well
plates when appropriate. For genotyping, cells were
pelleted and resuspended with 50ul of Lysis Buffer
(25 mM NaOH, 0.2 mM EDTA) and heated at 95 °C for
30 min [46]. The reaction was inactivated with Tris
Buffer (40 mM Tris–HCl) and lysates centrifuged for
5 min at 4000 rpm. 5ul of the supernatant was used dir-
ectly as a template for genomic PCR. For long amplicons
such as the MALAT1_E genotyping, the PCR with this
method did not work, and we extracted gDNA with
GeneJET Genomic DNA Purification Kit (Thermo Sci-
entific). A first PCR was done with primers flanking the
deleted region (Additional file 6: Table S4) as shown in
Fig. 4a. The absence of the wild type allele was recon-
firmed with a second PCR (primers in Additional file 6:
Table S5) that only amplifies WTallele as shown in Fig. 5c.
In order to identify inverted alleles, we performed a final
inversion PCR reaction using one external and one
inverted internal primer, as shown in Additional file 4:
Figure S4A (primers in Additional file 6: Table S6).
TA cloning
In order to sequence mutated alleles in homozygous
clones, we amplified junctions by PCR and cloned the
resulting PCR products by TA cloning (Life Technolo-
gies), according to manufacturer’s instructions, and se-
quenced by Sanger sequencing using the manufacturer’s
provided sequencing primer.
RNA extraction, reverse transcription and qPCR
RNA extractions from 5 × 105-2 × 106 cells were per-
formed with Quick RNA Miniprep Kit (Zymo Research).
DNAse treatment was performed on-column as indi-
cated. 150 ng-1ug RNA were retrotranscribed with Re-
verse Aid reverse transcriptase (Life Technologies). In all
cases, a control reaction was prepared without RTase
(“no RT”) in order to detect genomic DNA contamin-
ation. Quantitative PCR (qPCR) was performed with
SYBR Green master mix (Roche) and in LightCyclerR480
Real-Time PCR System (Roche). Primer sequences can
be found in Additional file 6: Table S7 and S8. All
quantifications were normalized to an endogenous con-
trol (Hipoxanthine-guanine phosphoribosyl transferase,
HPRT; or Glyderaldehyde 3-phosphate dehydrogenase,
GAPDH). The relative quantification value for each tar-
get gene compared with the calibrator is expressed as
2^(Ct-Cc). Products from the qPCRs were loaded in 2 %
agarose gels to check for correct size.
Cell proliferation assay
Cells were seeded at a density of 103 cells per well in
NUNC™ MicroWell™ 96-Well Microplates. Cell prolifer-
ation was monitored at 24 h, 48 h and 72 h incubating
cells with 0.4 mM Resazurin sodium salt (Sigma), dis-
solved in PBS, at 37 °C for 2.5 h. Resazurin fluorescence
was measured with an Infinite 200 PRO series multiplate
reader (TECAN) using 530 nm excitation and 590 nm
emission wavelengths.
Flow cytometry
Cells were trypsinized, pelleted and washed once with
PBS. Fc receptor blocker was used in order to prevent
nonspecific antibody binding. Cells were incubated with
α-human CD71 FITC (Bioscience, 11–0719) for 30 min
in the dark (note that CD71 is an alternative designation
for TFRC). Cells were rinsed with PBS + 3%FBS and
DAPI was added for marking cell viability. For the stain
index calculation we used the formula: (mean positive –
mean background) / (2 * SD background), as previously
described in [47].
Additional files
Additional file 1: Figure S1. The targeted region of the UCA1 gene. The
UCA1 gene locus, indicating the targeted promoter region. (PDF 349 kb)
Additional file 2: Figure S2. Genomic PCR of bulk cells transfected
with pDECKO constructs. (A) The deletion of TFRC_B promoter in
HEK293T cells is shown, (B) MALAT1_A in HEK293T cells and (C) HeLa
cells, (D) MALAT1_E promoter in HCT116 cells, (E) MALAT1_E promoter in
HEK293T and HeLa cells, and (F) UCA1 promoter in HEK293T cells. Wild
type gDNA and water are used as positive and negative controls,
respectively. Green and red arrows indicate the size of PCR products
expected from wild type and deleted alleles, respectively. (PDF 469 kb)
Additional file 3: Figure S3. qRTPCR of targeted genes in bulk cells. (A)
HEK293T cells with TFRC_B pDECKO, (B) with MALAT1_A pDECKO or (C)
HeLa cells with TFRC_B pDECKO, (D) with MALAT1_A pDECKO,(E) with
MALAT1_E in HeLa cells and (F) with MALAT1_E in HEK293T cells. Levels
were normalised to the HPRT gene expression (A-D) or to GAPDH (E-F).
Control indicates clonal pDECKO-GFP cells. (PDF 210 kb)
Additional file 4: Figure S4 Inverted PCRs for genotyping. (A) Diagram
of the genotyping primers configuration for detecting target site
inversions. Upper image: wild type; lower image: inversion. (B). Example
of PCR amplification of inverted fragment in HEK293T clones. MALAT1_D
KO was determined as non-inverted clone, while MALAT1_C KO has an
inversion. (C) Example of PCR amplification of inverted fragment in HeLa
clones. WT HeLa was used as negative control of the PCR. (PDF 23682 kb)
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Additional file 5: Figure S5. qRTPCR of MALAT1 with downstream
primers, complete data. RNA expression level is shown for MALAT1
clones in HEK293T and HeLa cells using different MALAT primer sets
(1 to 4) (see Fig. 2) and primers for HPRT. Levels were normalised to
GADPH. (PDF 286 kb)
Additional file 6: Table S1. gRNA targeting sequences. Table S2.
Sequences used to create Insert-2. Table S3. Sequencing primers for
pDECKO. Table S4. Genotyping primers (1st PCR). Table S5. Genotyping
primers (2nd PCR). Table S6. Genotyping primers (inversion PCR). Table S7.
Primers for gRNA detection. Table S8. qRTPCR primers. (DOCX 22 kb)
Additional file 7: File S1. Design tool for Insert-1 oligonucleotides.
(XLSX 6 kb)
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